The consequences of 'Brexit' for drug discovery and development, and the regulatory implications

Expert Opin Drug Discov. 2018 Jul;13(7):583-585. doi: 10.1080/17460441.2018.1463215. Epub 2018 Apr 15.

Authors

Bernard T Golding¹, Michael J Waring²

Affiliations

¹ a Chemistry, School of Natural & Environmental Sciences and Northern Institute for Cancer Research, Bedson Building , Newcastle University , Newcastle upon Tyne , UK.
² b Northern Institute for Cancer Research and Chemistry, School of Natural & Environmental Sciences, Bedson Building , Newcastle University , Newcastle upon Tyne , UK.

PMID: 29634365
DOI: 10.1080/17460441.2018.1463215

No abstract available

Keywords: Brexit; EMA; European medicines agency; FDA; Food & Drug Administration; drug development; drug discovery; drug regulation.

Publication types

Editorial

MeSH terms

Animals
Drug Development / legislation & jurisprudence*
Drug Discovery / legislation & jurisprudence*
Drug Industry / legislation & jurisprudence*
European Union
Humans
Legislation, Drug
United Kingdom